Non-small Cell Lung Cancer : News

Healthline's Premium Tools

Pill Finder
Search by color, shape and markings. click here
Drug Interaction Checker
Check any 2 drugs for interactions. click here
Drug Compare
Compare any two drugs side by side. click here
Healthline Part D Plan Selector Medicare Part D
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
London, UK, and Cambridge, MA, 15 August 2008 - Antisoma plc today announced survival data from its phase II study of ASA404 in hormone-refractory prostate cancer, in which patients were randomised to receive ...
Source:Market Wire
Date:August 14, 2008
A combination of two chemotherapy regimens may be a viable alternative to current treatments for non-small cell lung cancer.
Source:Ivanhoe's Medical Breakthroughs
Date:August 14, 2008
Main Category: Lung Cancer Also Included In: Medical Devices / Diagnostics ; Respiratory / Asthma ; Cancer / Oncology Article Date: 14 Aug 2008 - 2:00 PDT Accuray Incorporated , a global leader in the field of ...
Source:Medical News Today
Date:August 14, 2008
In a phase II multicenter study of 56 patients with an advanced form of this common lung cancer, endpoints including response rate, progression-free survival, and overall survival from use of S-1 and irinotecan ...
Source:Science Daily
Date:August 13, 2008
... Prodrug (HAP) that specifically targets tumor hypoxia. "Targeting tumor hypoxia is an exciting area of cancer research, and may offer great promise to patients with a wide variety of cancers," said Dr. Jeffrey Infante, M.D., Sarah Cannon Research ...
Source:PrimeNewswire
Date:August 12, 2008
Geron Corporation announced the enrollment of the first patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in locally recurrent or metastatic breast cancer.
Source:MediLexicon
Date:August 11, 2008
... focus on subjects such as Alzheimer's Disease, Benign Prostatic Hyperplasia, ADHD, Parkinson's Disease, Migraine, Non-Small Cell Lung Cancer and Hypertension. "Today's physicians are faced with an overwhelming challenge in keeping up-to-date with ...
Source:MediLexicon
Date:August 7, 2008
... and a significant Cyclacel presence at major oncology conferences during the quarter, have underscored our expertise in cell cycle science and our ongoing commitment to creating treatments for multiple cancers in which significant unmet need still ...
Source:BusinessWire
Date:June 30, 2008
Advertisement
Back to Top